Enveric Biosciences Inc. (ENVB)

Overview

Enveric Biosciences, Inc. stands at the forefront of biotechnological innovation, dedicating itself to the development of small-molecule therapeutics aimed at combating a host of mental health issues, including anxiety, depression, and addiction disorders. Rooted in a deep understanding of the complexities of mental health, Enveric Biosciences focuses on creating impactful treatments that can significantly improve the quality of life for those affected by these conditions. From its headquarters in Naples, Florida, the company harnesses the therapeutic potential of compounds like psilocybin and cannabinoids, positioning itself as a pioneer in the field of psychopharmacology.

Products and Services

• EB-373

An innovative therapeutic derived from an active metabolite of psilocybin, EB-373 is spearheading Enveric Biosciences’ efforts in addressing anxiety disorders. Currently in Phase 1 clinical trials, EB-373 exemplifies the company’s commitment to exploring the therapeutic frontiers of psychedelics for mental health treatment.

• EVM-301

Positioned as a versatile treatment within Enveric Biosciences’ pipeline, EVM-301 aims to redefine the landscape of mental health care. Though specific details on its mechanism and targets remain under wraps, EVM-301 underscores the company’s innovative approach to combating mental health issues.

• EV104 CBD + Celecoxib Conjugate

This unique formulation combines CBD, a non-psychoactive compound found in cannabis, with Celecoxib, a well-known anti-inflammatory drug. Together, they form a conjugate slated for the treatment of osteoarthritis, demonstrating Enveric Biosciences’ trajectory towards addressing chronic pain and inflammation through novel therapeutic avenues.

• Cannabinoid-infused Topical Product for Radiodermatitis

Delving into the realm of dermatological conditions, Enveric Biosciences is developing a cannabinoid-infused topical solution specifically designed for the treatment of radiodermatitis. This innovative product highlights the company’s versatility and commitment to leveraging cannabinoids’ therapeutic potential across various medical conditions.

• Cannabinoid and COX-2 Inhibitor Conjugation for OA/Acute Pain

In the pre-clinical stage, this novel conjugation aims to harness the synergistic effects of cannabinoids and COX-2 inhibitors to combat osteoarthritis and acute pain. This approach signifies Enveric Biosciences’ dedication to exploring and developing groundbreaking pain management solutions.